Biotherapeutics company CSL Limited said it has become aware that Shire ViroPharma filed a complaint in the US District Court for the District of Delaware alleging infringement of a newly granted US patent in connection with a method of treating Hereditary Angioedema (HAE).
“CSL remains highly confident that CSL830 does not infringe any valid claim of the Shire ViroPharma patent and will vigorously defend against the claims,” said CSL.
CSL said that in August 2016, the US Food and Drug Administration accepted for review CSL’s Biologics License Application for CSL830, CSL’s low-volume subcutaneous C1-esterase inhibitor (human) replacement therapy for the prevention of HAE attacks.
“This work is the product of independent research and development work at CSL Behring,” said CSL.
“Subject to US FDA approval, CSL is looking forward to bringing this exciting new therapy to patients later this year.”